Filing Details

Accession Number:
0000947871-23-001148
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-14 17:44:43
Reporting Period:
2023-12-12
Accepted Time:
2023-12-14 17:44:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1816736 Disc Medicine Inc. IRON () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
1682115 Orbimed Capital Gp Vi Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
1808744 Orbimed Genesis Gp Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
1845804 Orbimed Capital Gp Viii Llc 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-12-12 14,400 $60.16 1,182,425 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-12 9,300 $60.16 764,307 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-12 3,600 $60.16 295,605 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-13 56,200 $58.56 1,126,225 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-13 36,400 $58.56 727,907 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-13 14,100 $58.56 281,505 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-14 100 $57.73 1,126,125 No 4 S Indirect See footnotes
Common Stock Disposition 2023-12-14 100 $57.73 727,807 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Footnotes
  1. These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  2. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
  3. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
  4. This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.